 CAMBRIDGE, Mass., Sept. 8, 2021 PRNewswire -- Nuvalent, Inc., Nasdaq: NUVL, a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and business highlights and second quarter 2021 financial results. 